(R)-HTS-3 (GLXC-25878) is a potent, selective, and cell-active inhibitor of lysophosphatidylcholine acyltransferase 3 (LPCAT3) with an IC50 of 0.09 µM, an enzyme critical for synthesizing C20:4-containing phospholipids. It reduces arachidonic acid-d8 incorporation into phospholipids and mitigates RSL3-induced ferroptosis in HT-1080 and 786-O cancer cells.

(R)-HTS-3 (GLXC-25878) is a potent, selective, and cell-active inhibitor of lysophosphatidylcholine acyltransferase 3 (LPCAT3) with an IC50 of 0.09 µM, an enzyme critical for synthesizing C20:4-containing phospholipids. It reduces arachidonic acid-d8 incorporation into phospholipids and mitigates RSL3-induced ferroptosis in HT-1080 and 786-O cancer cells.

GSK840 (GSK’840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.